ScholarIQanswers from OpenAlex & ORCID
Patrick Schloemer
ResearcherPublications, citations & collaboration network
Patrick Schloemer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Patrick Schloemer have?
ScholarIQindexed works
Patrick Schloemer has 75 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Patrick Schloemer have?
ScholarIQcitation count
Patrick Schloemer has 3,964 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Patrick Schloemer?
ScholarIQh-index
Patrick Schloemer has an h-index of 15 in OpenAlex.
What is the i10-index of Patrick Schloemer?
ScholarIQi10-index
Patrick Schloemer has an i10-index of 19 in OpenAlex.
What is the ORCID of Patrick Schloemer?
ScholarIQorcid
The ORCID for Patrick Schloemer is on the source record.
What is the OpenAlex record for Patrick Schloemer?
ScholarIQopenalex
The OpenAlex for Patrick Schloemer is on the source record.
What are the most-cited papers on Patrick Schloemer?
ScholarIQmost cited works
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph, Gerasimos Filippatos
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, Bertram Pitt, Luís M. Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph, George L. Bakris, For the FIDELIO-DKD Investigators
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Christina Nowack, Peter Kolkhof, Anna Carolina Galvão Ferreira, Patrick Schloemer, Gerasimos Filippatos, on behalf of the FIDELIO-DKD study investigators
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund, Alasdair D Henderson, Meike Brinker, Peter Kolkhof, Patrick Schloemer, James Lay‐Flurrie, Prabhakar Viswanathan, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Peter Rossing, Luís M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J.V. McMurray, Scott D. Solomon
Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial
Muthiah Vaduganathan, Brian Claggett, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Akshay S. Desai, Pardeep S. Jhund, Prabhakar Viswanathan, Antonieta Bomfim Wirtz, Patrick Schloemer, James Lay‐Flurrie, John J.V. McMurray, Scott D. Solomon